Background: Little is known about secondary prevention of cardiovascular diseases, using cardio-protective drugs, in the community-level, especially in low-and middle-income countries. We aimed to assess main drug use and its predictors in Northeast of Iran. Methods: This is a cross-sectional analysis on the Golestan Cohort Study data (2004– 2008) with 50 045 participants. We assessed drug use in those with a history of ischemic heart disease (IHD) or stroke, recorded by face-to-face interviews. We explored drug use predictors (i. e., age, gender, wealth, education, residency, smoking, body mass index, physical activity, hypertension, and diabetes) through multivariable logistic regression. Results: A total of 3371 (6. 7%) participants (56. 7 ± 9. 0 years, 58. 1% female) reported a history of IHD, stroke or both. Median duration since diagnosis was 3. 14 years (IQR: 1. 25-6. 30). Rates of using anti-platelets, statins, angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers, and beta-blockers were 28. 8% (95% CI: 27. 3– 30. 3), 5. 4 (4. 7– 6. 2), 15. 7 (14. 5– 17. 0), and 40. 6 (38. 9– 42. 3), respectively. About 43% (41 – 45) of patients did not use any protective drugs. Use of ≥ three drugs was only 7. 3% (6. 6– 8. 2). Indicators of ≥ 1 drug use were: older age (OR for ≥ 60 vs. <50: 1. 37), high wealth score (fifth vs first quintile: 1. 60), literacy (1. 56), city dwelling (1. 32), body mass index (<18. 5 and ≥ 30 vs. 25– 29: 0. 55 and 1. 25, respectively), physical activity (third vs. first tertile: 0. 64), hypertension (3. 47), and diabetes (1. 29); (all P < 0. 05). Conclusion: Drug use after IHD or stroke is low in Northeast of Iran. Comprehensive efforts to promote secondary prevention are urgently needed.